Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Eli Lilly (NYSE: LLY ... The storied pharmaceutical company's shares lost nearly 5% of their value during the big market sell-off that day, and it wasn't only because of the general gloom.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Giftify (GIFT) announced a significant increase in gift card sales following its announcement of a smart savings program for GLP-1 diabetes and ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...